FR2939043B1 - Composition pour retarder l'initiation tumorale de cellules cancereuses chez un mammifere a risque - Google Patents

Composition pour retarder l'initiation tumorale de cellules cancereuses chez un mammifere a risque

Info

Publication number
FR2939043B1
FR2939043B1 FR0806715A FR0806715A FR2939043B1 FR 2939043 B1 FR2939043 B1 FR 2939043B1 FR 0806715 A FR0806715 A FR 0806715A FR 0806715 A FR0806715 A FR 0806715A FR 2939043 B1 FR2939043 B1 FR 2939043B1
Authority
FR
France
Prior art keywords
delaying
composition
cancer cells
tumor initiation
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0806715A
Other languages
English (en)
Other versions
FR2939043A1 (fr
Inventor
Sebastien Faure
Daniel Henrion
Nicolas Clere
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite dAngers
Original Assignee
Universite dAngers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite dAngers filed Critical Universite dAngers
Priority to FR0806715A priority Critical patent/FR2939043B1/fr
Priority to PCT/FR2009/052311 priority patent/WO2010061142A2/fr
Publication of FR2939043A1 publication Critical patent/FR2939043A1/fr
Application granted granted Critical
Publication of FR2939043B1 publication Critical patent/FR2939043B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
FR0806715A 2008-11-28 2008-11-28 Composition pour retarder l'initiation tumorale de cellules cancereuses chez un mammifere a risque Expired - Fee Related FR2939043B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR0806715A FR2939043B1 (fr) 2008-11-28 2008-11-28 Composition pour retarder l'initiation tumorale de cellules cancereuses chez un mammifere a risque
PCT/FR2009/052311 WO2010061142A2 (fr) 2008-11-28 2009-11-26 Composition pour retarder l'initiation tumorale de cellules cancéreuses chez un mammifère a risque

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0806715A FR2939043B1 (fr) 2008-11-28 2008-11-28 Composition pour retarder l'initiation tumorale de cellules cancereuses chez un mammifere a risque

Publications (2)

Publication Number Publication Date
FR2939043A1 FR2939043A1 (fr) 2010-06-04
FR2939043B1 true FR2939043B1 (fr) 2011-03-04

Family

ID=40404073

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0806715A Expired - Fee Related FR2939043B1 (fr) 2008-11-28 2008-11-28 Composition pour retarder l'initiation tumorale de cellules cancereuses chez un mammifere a risque

Country Status (2)

Country Link
FR (1) FR2939043B1 (fr)
WO (1) WO2010061142A2 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0551432A1 (fr) * 1990-10-02 1993-07-21 Warner-Lambert Company Derives et analogues de 4,5,6,7-tetrahydro-1h-imidazo 4,5-c]pyridine utilises comme antagonistes des recepteurs de l'angiotensine ii
WO2002087503A2 (fr) * 2001-04-26 2002-11-07 Vanderbilt University Compositions et methodes de traitement des polypes colorectaux et du cancer colorectal
CA2466659A1 (fr) * 2001-11-13 2003-05-22 Takeda Chemical Industries, Ltd. Agents anticancer
CA2668725A1 (fr) * 2006-11-09 2008-05-22 Ore Pharmaceuticals Inc. Procedes de depistage et de traitement du cancer du sein

Also Published As

Publication number Publication date
FR2939043A1 (fr) 2010-06-04
WO2010061142A2 (fr) 2010-06-03
WO2010061142A3 (fr) 2010-08-12

Similar Documents

Publication Publication Date Title
HK1154859A1 (zh) 用於治療癌症的異吲哚啉化合物
IL230771A (en) Antibody from a person that binds pcsk9
IL206970A0 (en) Compositions and methods for the treatment of tumor of hematopoietic origin
SI2200431T1 (sl) Sestave in metode za zdravljenje raka
EP1990418A4 (fr) Adenovirus oncolytiques destines au traitement du cancer
IL207295A (en) The vehicle containing Degarelix for use in the treatment of particular prostate cancer diagnosed as having a risk of cardiovascular disease
PL2340042T3 (pl) Sposoby i kompozycje do leczenia raka
ZA201102035B (en) Methods and formulations for treating chronic liver disease
HK1151734A1 (en) Therapeutic for hepatic cancer
IL200251A0 (en) Compositions and methods to prevent cancer with cupredoxins
EP2231185A4 (fr) Procédés et compositions pour traiter des tumeurs liquides
IL200764A0 (en) Composition comprising epha3 antibodies and use thereof for the treatment of solid tumors
EP2300608A4 (fr) Procédés de traitement des tumeurs solides
HK1143157A1 (en) 4-pyridinone compounds and their use for cancer 4-
HK1256479A1 (zh) 在治療癌症中grn163l用作端粒酶抑制劑
EP2150270A4 (fr) Méthodes et compositions pour traiter le cancer
HK1151971A1 (en) Compounds for use in the treatment of cancer
HK1218857A1 (zh) ' - ' - '- 用於腎臟細胞癌的治療的 '， '-四羥基- '-聯吡啶- '-二氧化物
EP1996211A4 (fr) Compositions de gallium pour le traitement du cancer du foie et procédés d'utilisation
IL213636A0 (en) Compositions and methods to prevent cancer with cupredoxins
SG10201700334XA (en) Composition useful for the prevention or reduction of the progression of prostate cancer
HU0800156V0 (en) Improved aid for facilitate the moving of cables in culverts
EP2321353A4 (fr) Anticorps modulant la différenciation et la fonction de cellules dendritiques par la molécule d'adhésion intercellulaire de liaison-1 et son utilisation
FR2939043B1 (fr) Composition pour retarder l'initiation tumorale de cellules cancereuses chez un mammifere a risque
WO2010022268A9 (fr) Marqueurs pour évaluer la sensibilité d'un cancer à un traitement igf-1r

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20130731